A single dose of psilocybin (the psychedelic compound from magic mushrooms) can produce a “statistically significant” reduction in symptoms for people with obsessive-compulsive disorder (OCD), all with “no serious adverse events,” according to a new study published in Comprehensive Psychiatry.
O pesquisa, conducted by scientists at the University of Hertfordshire and Imperial College London, explored the potential of psilocybin therapy to help people manage the challenging symptoms of OCD. The study involved 19 participants diagnosed with the condition to see whether this psychedelic-assisted approach could offer relief from compulsive behaviors.
What is OCD?
Obsessive-compulsive disorder is a mental health condition that affects millions of people worldwide. It is characterized by intrusive, unwanted thoughts (obsessões) and repetitive behaviors or mental rituals (compulsões) that individuals feel compelled to perform to reduce anxiety. OCD is not about simply liking things “neat and tidy.” It can be deeply distressing, time-consuming, and can significantly interfere with daily life. Traditional treatments often include a combination of therapy, such as cognitive-behavioral therapy (CBT), and medications like SSRIs, but not everyone responds well to these approaches. That’s why research into alternative treatments, like psilocybin, is so important.
How Did The Study Work?
In the study, participants were given two doses of psilocybin over four weeks: one milligram and 10 milligrams. Both doses appeared to help reduce OCD symptoms, but the researchers found that the 10 mg dose was especially “well-tolerated and potentially efficacious in patients” with the condition.
“Psilocybin produced a rapid-onset, moderate to large effect on compulsive symptoms, which lasted up to one week after dosing,” the study reported. “10 mg of oral psilocybin was acceptable for and well-tolerated by patients with OCD.”
However, the effects seemed to fade about two weeks after the treatment, leading the authors to conclude that a 10 mg dose “can achieve a rapid onset of a relatively short-lived improvement in OCD symptomatology.”
OCD Sufferers are Keen for New Treatment Options
The researchers also noted that there was a strikingly high volume of interest among prospective participants, suggesting that “there is a significant interest for psilocybin in the OCD community.”
While the results are promising, the team pointed out that the small number of participants is a limitation. They stressed the need for follow-up studiesF with larger groups of patients and over longer periods to gather more robust data.
No Negative Effects Were Reported
Importantly, no serious adverse events were reported. This aligns with a scientific review published by the American Medical Association (AMA) last year, which found that single-dose psilocybin use is “not associated with risk of paranoia,” and that mild side effects such as headaches are typically “tolerable and resolved within 48 hours.”
Psilocybin’s potential isn’t limited to OCD. A ensaio clínico published by the AMA in December suggested both the safety and efficacy of psilocybin-assisted psychotherapy for bipolar II disorder — a condition known for its difficult-to-treat depressive episodes. Another AMA study from August encontrado that people with major depression experienced a “clinically significant sustained reduction” in symptoms after just one dose of psilocybin.
Obsessive compulsive disorder comes in many forms, however, until now its treatment was sadly lacking. These strides forward in research are a light at the end of the tunnel for those whose lives have been dogged by the symptoms of this difficult condition. Watch this space…
